Background: Discussion is ongoing regarding whether associating liver partition with portal vein ligation for staged hepatectomy (ALPPS) or portal vein occlusion is better in staged hepatectomy. The aim of this study was to compare available strategies using a two-stage approach in extended hepatectomy.
Introduction
Liver resection is the first-line treatment for many liver malignancies, offering the best chance for long-term survival 1, 2 . The main reason for poor postoperative outcomes is inadequate volume of the future liver remnant (FLR), which leads to posthepatectomy liver failure 1, 3 . Several strategies have been developed over the past two decades to induce compensatory hypertrophy of the FLR, thereby increasing the chance of resectability and lowering the risk of postoperative complications 1,4 -6 . Most strategies induce liver hypertrophy by manipulation of the portal blood flow. Although this concept was first emphasized by Cantlie in 1897, and later by Rous in 1920 7 , clinical implementation occurred only in 1975 with portal vein ligation (PVL) introduced by Honjo and colleagues 4 . PVL is used routinely in two-stage procedures, where sometimes a 'cleansing' of the FLR from tumour is performed along with PVL. After reaching adequate hypertrophy of the FLR, resection of the diseased liver part is undertaken during a second stage. Portal vein embolization (PVE), by injecting embolizing agents in one of the portal branches, was introduced by Kinoshita et al. 5 and Makuuchi and co-workers 8 in the late 1980s. This approach gained wide acceptance in liver surgery over the following decades. The two methods have been compared in the literature with regard to hypertrophy of the FLR, with controversial results 9 -11 . The major issue in these two-stage approaches is the potential drop-out of up to 35 per cent of patients because of either insufficient liver hypertrophy of the FLR or tumour progression within the 4-6-week interval between portal vein occlusion and resection 12, 13 .
Recently, a novel technique of two-stage liver resection was introduced, combining PVL and transection of the liver between the FLR and the deportalized part of the liver 6, 14 ; this is known by the acronym ALPPS (associating liver partition with PVL for staged hepatectomy) 14 . ALPPS has been reported to induce hypertrophy of the FLR of up to 80 per cent in a shorter time than PVL or PVE 14, 15 . However, this procedure has triggered serious concerns owing to the associated high morbidity and mortality rates of up to 40 and 15 per cent respectively 16 . Other attempts have been made to induce liver regeneration by occlusion of unilateral hepatic veins or hepatic artery 17, 18 , but these approaches have never reached wide acceptance because no advantage over PVE or PVL has been demonstrated.
This variety of methods to overcome the issue of a small FLR has created a dilemma in selecting the optimal strategy in daily practice. Two recently published systematic reviews 19, 20 of two-stage hepatectomy are available. No non-comparative studies were included in the first of these 19 and only 32 patients undergoing ALPPS were included in the analysis. The second systematic review 20 suffered from biases related to oversight in search strategy, and was subsequently retracted at the request of the authors.
The purpose of the present review was to assess the efficacy of the ALPPS and PVL/PVE strategies used to increase FLR volume before extended liver resection in patients with primary or secondary liver malignancies. The main endpoints were comparison of volumetric changes, feasibility of the second stage, rate of resection-free margins (R0), as well as postoperative morbidity and mortality after PVE, PVL, ALPPS and other less frequently performed strategies.
Methods

Search strategy and study selection criteria
A comprehensive systematic search of the databases MEDLINE, Scopus, the Cochrane Library and Embase was conducted using the following terms: 'portal vein embolization', 'portal vein ligation', 'portal vein occlusion', 'hepatic vein embolization', 'hepatic vein ligation', 'hepatic vein occlusion', 'bile duct ligation', 'bile duct occlusion', 'ALPPS' and 'hepatectomy (liver resection or hepatic resection or surgery or transection or partition)'. Both comparative and non-comparative studies of a variety of strategies, including PVE, PVL, ALPPS, hepatic vein occlusion and bile duct occlusion, were identified. The complete search strategy can be found in Table S1 (supporting information). The last electronic search was on 17 July 2014. A limited update search with access to the ALPPS registry was performed on 18 January 2015. There were no language or time restrictions. Additional articles were identified by hand searching. Corresponding authors of included publications were asked for missing information. If the e-mail address provided in the publication was no longer valid, the first author was contacted by e-mail. This systematic review was registered in the international PROSPERO database (CRD420150102439) (http://www.crd.york.ac.uk/PROSPERO/).
The following types of clinical study were included: case series with ten or more patients, case-control studies, cohort studies and RCTs. All other types were excluded. Articles reporting only on patients with liver cirrhosis were excluded.
Data extraction and quality assessment
Two reviewers screened the abstracts independently to identify studies for full-text analysis following the abovementioned criteria. Discrepancies between reviewers were resolved after discussion between them and two senior authors. New data provided on request by corresponding authors were included for analysis. The level of evidence of included studies was assessed based on the definitions of the Oxford Centre for Evidence-based Medicine 21 . Risk of bias in individual studies was assessed by means of the Newcastle-Ottawa quality assessment scale 22 .
Data collection and measures
Descriptive data were collected including: tumour type, chemotherapy before stage 1, biliary drainage for decompression, liver cirrhosis and number of occluded liver segments after PVE or PVL. Volumetric data for the FLR were collected before stage 1 and stage 2, including volume of FLR (ml), FLR (per cent; calculated as FLR/total liver volume × 100) or standardized FLR per cent 23 and volumetric changes after stage 1 (including absolute increase in volume and hypertrophy ratio of FLR). Time between stage 1 and follow-up CT or stage 2 was reported separately.
The feasibility rate of stage 2 was recorded, where feasibility was defined as completion of liver resection at stage 2. Investigated reasons for not proceeding to stage 2 included intrahepatic and extrahepatic tumour progression and failure of the FLR to hypertrophy.
The total number of patients with complications was determined. In comparative studies between ALPPS and other strategies, morbidity after ALPPS was analysed including both stage 1 and 2, as complications occur during the same hospital stay and information for each patient summarized the whole admission. Where complications after stages 1 and 2 of ALPPS had been reported separately, the highest rate of complications was used for analysis. For the other strategies, only complications after stage 2 were considered for comparison with ALPPS, as often only these were recorded and most complications occur solely after stage 2 in such strategies. Complications after stage 1 and stage 2 were not added, because the same patient could have complications after stage 1 as well as after stage 2, leading to incorrect analysis. In comparative studies without ALPPS, stage 1 and stage 2 were compared separately. In non-comparative studies, morbidity was reported separately after stage 1 and stage 2. Severity of complications was also assessed for each strategy using the Clavien-Dindo classification 24 . Mortality was reported as in-hospital and 90-day mortality. Mortality after stage 1 and stage 2 was analysed separately for each strategy. Resection margins were considered as R0 or R1 depending on the reported clearance of the FLR. Overall and disease-free survival rates were not analysed owing to missing data after ALPPS procedures and the heterogeneity of tumour type 15 .
Statistical analysis
Missing data for mean and standard deviation were calculated from reported median and range values 25 , unless the corresponding authors provided the actual data.
For the quantitative synthesis of comparative studies, a fixed-effect or random-effects meta-analysis was used as appropriate, with standardized mean differences reported for continuous outcomes and risk ratios (RRs) for binary outcomes, along with 95 per cent confidence intervals (c.i.) and two-sided P values for each outcome. These analyses were carried out in Review Manager (RevMan) version 5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark).
The summaries of intervention effects for single-group, non-comparative studies were similarly reported using Comprehensive Meta-Analysis software (Biostat, Englewood, New Jersey, USA) with random-effects meta-analysis.
Heterogeneity between the studies in effect measures was assessed using both the χ 2 test and the I 2 statistic.
Results
Identification of studies
The systematic literature search identified 2796 publications. After excluding duplicates, 1491 publications were screened. Five additional publications 11,26 -29 were identified from other sources. Additionally, data from 320 patients who underwent ALPPS were extracted from the international ALPPS registry 30 . In total, 172 publications were eligible for full-text review, 82 of which were excluded from the final analysis (Fig. 1) . One study reported on portal vein occlusion as a combination of PVE and PVL and was excluded because the authors did not provide any raw data 31 . Nine studies were comparative: seven 9 -13,32,33 compared PVE versus PVL, one 34 compared PVE versus ALPPS, and one 14 compared PVE or PVL versus ALPPS ( Table 1) . The remaining 81 studies described single cohorts ( Table 2 ). Only one study reported on occlusion of hepatic veins 17 . No study concerning occlusion of bile ducts for induction of hepatic hypertrophy in humans was identified.
Evidence level and quality assessment of studies
The majority of included studies were classified as evidence level 3 or 4 (Tables 1 and 2). Some comparative studies were classified as evidence level 4 owing to the small numbers of included patients.
Descriptive information
The analysis included a total of 3670 patients after PVE, 290 after PVL and 367 after ALPPS. Of these, 179 patients after PVE, 123 patients after PVL and 55 patients after ALPPS were included in comparative studies. Most studies were highly heterogeneous and did not report on the number of deportalized liver segments, administration of chemotherapy, placement of biliary drainage or pre-existing cirrhosis (Table S2 , supporting information). In some reports on PVL, a small number of patients underwent PVE as well.
Speed of future liver remnant hypertrophy before resection
In the comparative studies, the percentage increase in FLR was similar after PVE and PVL in four studies 9 -11,14 with 99 patients in the PVE group and 74 in the PVL group (46 versus 35 per cent; mean difference (MD) 9⋅34, 95 per cent c.i. -1⋅81 to 20⋅48; P = 0⋅10) (Fig. S1a, supporting information). Heterogeneity among studies was moderate and not significant (P = 0⋅10; I 2 = 52 per cent). The percentage FLR increase was greater after ALPPS than PVE in two studies 14, 34 with 55 patients in the ALPPS group and 64 in the PVE group (76 versus 37 per cent; MD 39⋅66, 16⋅94 to 62⋅38; P < 0⋅001) (Fig. S1b , supporting information). Heterogeneity among studies was moderate and not Records screened for retrieval n = 1497
Potentially appropriate records to be included in systematic review n = 90
Records in meta-analysis n = 90
Records excluded from meta-analysis n = 0
Irrelevant records excluded after screening abstracts n = 1325
Records excluded n = 82 Overlapping patient cohorts n = 46 Unrelated to review question n = 21 Only patients with cirrhosis n = 7 Fewer than 10 patients n = 5 Letter/editorial n = 2 Mixture of data for PVE and PVL n = 1
Full-text articles assessed for eligibility n = 172 12 Germany PVE/PVL 17/17 3b 9 Capussotti et al. 13 Italy/France PVE/PVL 31/17 3b 9 Knoefel et al. 34 Germany PVE/ALPPS 15/7 4 8 Iida et al. 32 Japan PVE/PVL 9/4 4 7 Robles et al. 10 Spain PVE/PVL 18/23 3b 9 Schadde et al. 14 Switzerland PVE/PVL/ALPPS 51/32/48 3b 8 Stavrou et al. 33 Germany PVE/PVL 6/6 4 5 van Lienden et al. 11 The Netherlands PVE/PVL 14/7 4 6 PVE, portal vein embolization; PVL, portal vein ligation; ALPPS, associating liver partition with PVL for staged hepatectomy.
significant (P = 0⋅15; I 2 = 52 per cent). Only one study 14 compared ALPPS versus PVL, in which ALPPS induced a greater increase in FLR than PVL (mean(s.d.) 87(52) versus 29(29) per cent; P < 0⋅001). In the non-comparative studies, the mean(s.e.m.) FLR increase was 38(2) per cent after PVE in 32 studies, 35 (2) per cent after PVL in five studies and 81(3) per cent after ALPPS in four studies (Fig. S2, supporting information) . The mean(s.e.m.) time from stage 1 to follow-up CT volumetry was 26(1) days after PVE, 61(12) days after PVL and 12(0⋅5) days after ALPPS. The initial FLR volume was smaller in patients undergoing ALPPS than among those having PVE or PVL. Volumetric data for the different strategies are summarized in Table S3 (supporting information). Kinetic growth rates could not be reported because of lack of raw data and heterogeneity of time interval between stage 1 and imaging among studies.
Safety
In the comparative studies, complication rates were similar between the PVE and PVL groups (adjusted rates 36⋅2 versus 41⋅3 per cent) after stage 2 in five studies 9, 10, 13, 14, 32 with 102 patients in the PVE group and 72 in the PVL group (RR 0⋅99, 95 per cent c.i. 0⋅61 to 1⋅60; P = 0⋅96) (Fig. 2a) . Heterogeneity among studies was moderate and not significant (P = 0⋅19; I 2 = 38 per cent). A comparison of complications after stage 1 was not performed. Adjusted 36 Italy PVE 20 3b 7 Barbaro et al. 37 Italy PVE 26 4 6 Bellemann et al. 38 Germany PVE 21 4 6 Bent et al. 39 UK PVE 16 4 6 Cazejust et al. 40 France PVE 63 4 6 Chung et al. 41 Korea PVE 16 4 6 Cotroneo et al. 42 Italy PVE 31 4 5 Covey et al. 43 USA PVE 100 3b 8 de Baere et al. 44 France PVE 107 4 6 de Graaf et al. 45 The Netherlands PVE 24 4 6 Denecke et al. 18 Germany PVE/AE 25/25 1c RCT Ebata et al. 46 Japan PVE 494 4 5 Fischman et al. 47 USA PVE 35 4 6 Fujii et al. 48 Japan PVE 30 4 6 Giraudo et al. 49 France PVE 145 4 6 Grandadam et al. 50 France PVE 13 4 7 Guiu et al. 51 Switzerland PVE 34 4 9 Hemming et al. 52 USA PVE 39 3b 9 Hirai et al. 53 Japan PVE 30 4 5 Homayounfar et al. 54 Germany PVL 24 4 6 Hong et al. 55 Korea PVE 35 4 9 Huang et al. 56 USA PVE 152 4 9 Hwang et al. 17 Korea HVO/PVE 12 4 6 Imamura et al. 57 Japan PVE 84 4 6 Kakizawa et al. 58 Japan PVE 14 4 6 Kalenderian et al. 59 France* PVE 17 4 5 Kang et al. 60 Korea PVE 11 4 9 Kasai et al. 61 Japan PVE 59 4 6 Kim et al. 62 Korea PVE 11 4 6 Ko et al. 28 Korea PVE 51 4 6 Kotenko et al. 63 Russia* PVE 86 4 6 Kuo et al. 64 Australia PVE 25 4 6 Ladurner et al. 65 Austria PVE 19 4 6 Lee et al. 66 Japan PVE 10 4 6 Libicher et al. 67 Germany PVE 10 4 6 Lindnér et al. 68 Sweden PVE 19 3b 9 Liska et al. 69 Czech Republic* PVE 24 4 6 Lygidakis et al. 70 Greece PVL 62 4 6 Mailey et al. 71 USA PVE 20 4 6 Massimino et al. 72 USA PVE 23 4 9 Mathisen et al. 73 Norway PVE 18 4 6 Mihara et al. 74 Japan PVE 203 4 7 Nadalin et al. 75 Germany ALPPS 15 4 6 Nafidi et al. 76 Canada PVE 20 4 5 Nanashima et al. 77 Japan PVE 30 3b 5 Okabe et al. 78 Japan PVE 36 4 8 Pamecha et al. 79 UK PVE 36 4 8 Peregrin et al. 80 Czech Republic PVE 22 4 6 Peynircioglu et al. 81 Turkey PVE 20 4 5 Polishchuk et al. 82 Russia PVL 52 4 7 Popescu et al. 83 Romania PVL 15 4 6 Radeleff et al. 84 Germany PVE 13 4 6 Ratti et al. 85 Italy PVE 62 4 5 Regimbeau et al. 86 France PVE 18 4 6 Sakamoto et al. 87 Japan PVE 68 3b 8 Sakuhara et al. 88 Japan PVE 143 4 7 Schnitzbauer et al. 6 Germany ALPPS 25 4 7 Shah et al. 89 Belgium PVE 66 4 5 91 Korea PVE 30 4 6 Simoneau et al. 92 Canada PVE 109 4 6 Sirichindakul et al. 93 Thailand PVE 29 4 5 Srisud et al. 94 Thailand PVE 25 4 7 Sturesson et al. 95 Sweden PVE 26 4 6 Sugawara et al. 96 Japan PVE 66 4 8 Szijártó et al. 97 Hungary PVL 14 4 5 Tanaka et al. 98 Japan PVE 21 4 7 Tarazov et al. 99 Russia PVE 20 4 7 Treska et al. 100 Czech Republic PVE 38 4 6 Tsim et al. 101 UK PVE 36 3b 7 Tsuda et al. 102 Japan PVE 22 4 6 Turrini et al. 103 France PVE 42 4 8 Vyas et al. 29 UK PVE 31 4 7 Wakabayashi et al. 104 Japan PVE 17 4 8 Wichters et al. 105 France PVE 99 4 9 Yamashita et al. 106 Japan PVE 64 3b 7 Yi et al. 107 China PVE 16 3b 6 Yoo et al. 26 Korea PVE 41 4 6 Zboril et al. 108 Czech mortality rates were 6⋅3 and 9 per cent in the PVE and PVL groups respectively after stage 2 (RR, 0⋅77, 0⋅27 to 2⋅18; P = 0⋅62) (Fig. 2b) . There was no heterogeneity among included studies (I 2 = 0 per cent). Comparison of morbidity between the ALPPS and PVE groups was available in two studies 14, 34 with 55 patients in the ALPPS group and 51 in the PVE group. Complication rates were 73 per cent after ALPPS and 59 per cent after PVE (RR 1⋅22, 0⋅92 to 1⋅61; P = 0⋅16) (Fig. 2c) . There was no heterogeneity among included studies (P = 0⋅64; I 2 = 0). Adjusted mortality rates were 7 per cent after PVE and 14 per cent after ALPPS (RR 2⋅20, 0⋅68 to 7⋅09; P = 0⋅19) (Fig. 2d) . There was no heterogeneity among included studies (I 2 = 0 per cent). Only one study 14 compared ALPPS versus PVL. In this study, morbidity and mortality rates were 73 and 15 per cent respectively after ALPPS versus 62 and 8 per cent after PVL.
In the non-comparative studies, the complication rate was 17 (95 per cent c.i. 9 to 31) per cent after stage 1 in the PVL group (3 studies). Complications after stage 1 in the PVE group were not analysed, as the authors reported only relevant complications or used different definitions (Society of Interventional Radiology recommendation 109 or the National Cancer Institute's Common Terminology Criteria for Adverse Events 110 ) 26, 40, 84 . In the PVE group, four deaths were identified after stage 1 49, 63, 95 . The causes of death were circulatory collapse, bleeding, pulmonary embolism and septic shock. There was no death after stage 1 in the PVL group in the included studies.
After stage 2, the complication rates were 39 (33 to 44) per cent in the PVE group (38 studies) and 47 (3 to 60) per cent in the PVL group (8 studies). The complication rate including stage 1 and stage 2 was 70 (55 to 81 per cent) in the ALPPS group (3 studies). The severity grade of complications after stage 2 was inconsistently reported, with different definitions among studies. Therefore, no analysis of complication severity was possible.
Ninety-day mortality was reported inconsistently and so only in-hospital mortality was analysed. After stage 2, mortality rates were 5 (4 to 6) per cent in the PVE group (55 studies) and 7 (4 to 12) per cent in the PVL group (11 studies). In three studies reporting the results after extended right hepatectomy in the PVE group, the mortality rate was 8 (3 to 21) per cent. In the ALPPS group, the mortality rate was 12 (7 to 21) per cent in four studies, including mortality after stage 1, which was 2 per cent for the ALPPS registry.
Feasibility of second stage
In the comparative studies 9,10,12 -14,32,33 , the feasibility rate of stage 2 was similar in the PVE (150 patients) and PVL (116) Aussilhou et al. 9 Capussotti et al. 13 Iida et al. 32 Robles et al. 10 Schadde et al. 14 
Total
Heterogeneity: 2 = 0·09; 2 = 4·80, 3 d.f., P = 0·19; I 2 = 38T est for overall effect: Z = 0·05, P = 0·96 Aussilhou et al. 9 Capussotti et al. 13 Broering et al. 12 Stavrau et al. 33 Iida et al. 32 Robles et al. 10 Schadde et al. 14 Total Heterogeneity: 2 = 2·19, 4 d.f., P = 0·70; I 2 = 0T est for overall effect: Z = 0·49, P = 0·62 0·1 Knoefel et al. 34 Knoefel et al. 34 Schadde et al. 14 Schadde et al. 14 
Heterogeneity: 2 = 0·21, 1 d.f., P = 0·64; I 2 = 0T est for overall effect: Z = 1·39, P = 0·16 0·1 Aussilhou et al. 9 Capussotti et al. 13 Broering et al. 12 Stavrau et al. 33 Iida et al. 32 Robles et al. 10 Schadde et al. 14 Schadde et al. 14 Knoefel et al. 34 Total Heterogeneity: 2 = 5·46, 6 d.f., P = 0·49; I 2 = 0T est for overall effect: Z = 0·71, P = 0·48 0·1
Favours PVL Favours PVE (Fig. 3a) . There was no heterogeneity among included studies (P = 0⋅49; I 2 = 0 per cent). The tumour-free resection margin rates were 94 per cent in the PVE group and 92 per cent in the PVL group (RR 1⋅01, 0⋅92 to 1⋅11; P = 0⋅86). There was no heterogeneity among included studies (I 2 = 0 per cent). After ALPPS (55 patients) and PVE (66) the feasibility rates of stage 2 were 100 versus 77 per cent respectively (RR 1⋅28, 1⋅12 to 1⋅48; P < 0⋅001) 14, 34 (Fig. 3) . There was no heterogeneity among included studies (I 2 = 0 per cent). Only one study 14 compared resection margin status between ALPPS and PVE procedures; tumour-free resection margin rates were 98 and 97 per cent respectively 14 . In the only study 14 that compared ALPPS versus PVL, feasibility rates of stage 2 were 100 and 78 per cent respectively. The tumour-free resection margin rates were 98 versus 88 per cent. In the non-comparative studies, the feasibility rate of stage 2 in the PVE group was 77 (95 per cent c.i. 73 to 80 per cent) in 72 studies. The causes of failure to proceed to stage 2 were not reported in all studies. The main reasons for failure were extrahepatic tumour progression in 10 (9 to 13) per cent (50 studies) and intrahepatic tumour progression in 9 (6 to 11) per cent of the patients. The scheduled second stage was cancelled in 6 (4 to 7) per cent because of insufficient hypertrophy (68 studies). Tumour-free resection margin rates were 81 (74 to 87) per cent (27 studies). The feasibility rate of stage 2 after PVL was 72 (64 to 80) per cent in 12 studies. The main reasons for failure were extrahepatic tumour progression in 11 (7 to 16) per cent (9 studies) and intrahepatic tumour progression in 11 (7 to 17) per cent (9 studies). The scheduled second stage was cancelled in 7 (5 to 13) per cent of the patients because of insufficient hypertrophy (11 studies). The tumour-free resection margin rate was 92 (83 to 96) per cent (5 studies). The feasibility rate of stage 2 in the ALPPS group was 98 (96 to 99) per cent (4 studies). The main reason for failure was death after stage 1. Tumour-free resection margin rates were 91 (76 to 97) per cent (2 studies).
Discussion
This systematic review and meta-analysis targeted available strategies aiming at increasing small FLR before extended liver resection in patients with primary or secondary liver malignancies. The main findings are that ALPPS induces a greater degree of hypertrophy of the FLR in a shorter time than PVL and PVE, that the likelihood of achieving a complete tumour-free resection with an acceptable R0 margin rate is superior following ALPPS than after conventional two-step procedures, and that there is a trend towards higher morbidity and mortality after ALPPS. The main reasons for not proceeding with the second step after PVE or PVL are intrahepatic or extrahepatic tumour progression.
Intrahepatic portal collaterals between the FLR and occluded portal part of the liver have been implicated in the failure of the FLR to hypertrophy after PVE and PVL 11, 91 . Indeed, the increase in FLR correlates negatively with persistence of portal flow in occluded liver segments in humans 91 . This finding has also been documented in pig models of PVL and PVE. Four weeks after PVE, and also after PVL, portal 'neo' collaterals develop within the liver, although fewer after PVE than after PVL 111 . Portal vein collaterals are impossible anatomically following ALPPS. Interestingly, when the ALPPS procedure was modified by using a tightly knotted tourniquet around Cantlie's line, or between the left and middle hepatic veins instead of transecting the parenchyma, the reported median increase in FLR (61 per cent) was slightly less than after the original ALPPS procedure 112 . This might be explained by the development of collaterals through non-transected liver parenchyma. Another mechanism for the rapid hypertrophy of the FLR after ALPPS is the release of circulatory cytokines and growth factors induced by liver transection. In a mouse model, these circulatory factors have been shown not to be liver-specific, as similar effects can be obtained by injuring other organs. The rapid hypertrophy of the FLR after PVL combined with injection of plasma obtained from mice after the first step in ALPPS strongly pointed to the pivotal role of growth factor release, rather than simple devascularization between the part of the liver to be resected and the FLR 113 .
The volume increase of the FLR does not adequately reflect appropriate FLR function. Such a rapid volume increase raises the question of whether this is related to liver hypertrophy only (hepatocyte proliferation) or whether other factors, such as oedema or steatosis, may contribute to the increase in FLR. It has been shown that liver resection induces a systemic and intrahepatic hyperdynamic circulation 114 . This may lead to extravasal fluid accumulation causing parenchymal oedema 115 . It has also been recognized that intracellular lipid accumulation is increased after partial hepatectomy and this may also contribute to the volume gain of the FLR in ALPPS 116 .
Intravenous injections of [ 13 C]methacetin (LiMAx test) or indocyanine green plasma clearance rate are not informative for liver function assessment in staged procedures because the diseased part of the liver is still functional and influences the metabolism of these metabolites 74, 117 . Hepatobiliary scintigraphy was recently revisited as a quantitative method for evaluating total and regional liver function 118, 119 . Currently hepatobiliary scintigraphy with 99m Tc-labelled mebrofenin seems to be the most adequate tool for assessing quantitative function in FLR, and could be used in decision-making before liver resection, especially before undertaking stage 2 52 .
Some authors have challenged the ALPPS procedure, arguing that an equivalent increase in the FLR occurs after right PVE combined with segment IV embolization 16 . Segment IV portal branch occlusion is indicated only when complete removal of segment IV is planned. From a technical point of view, it may expose patients to spillage of embolization material in the FLR, compromising completion of the second step 47, 63 . It does not reduce the time between embolization and liver resection, and this exposes patients to tumour progression or to development of new metastases.
This review has shown that ALPPS is associated with a trend towards higher morbidity and mortality compared with PVE and PVL. The first analysis of the international ALPPS registry 14 showed that better selection of patients and indications decreased mortality and morbidity rates. Indeed, although a 9 per cent mortality rate was reported when patients with mixed types of tumours underwent ALPPS, this decreased to 5 per cent in patients aged less than 60 years with colorectal liver metastasis, who could not have undergone resection otherwise. This figure matches mortality rates of the largest series of conventional two-step hepatectomy 120, 121 . An interesting finding of the present analysis was the adjusted mortality rate in the PVL and PVE groups after extended right hepatectomy, which was higher than reported in these large series 120, 121 .
It is noteworthy that complications after stage 1 and stage 2 in the PVE and PVL groups were not summed owing to missing data. If data were available to sum complications in the correct way, the complication rates after PVE and PVL would be higher than reported in this review. The heterogeneity of complication grading systems prevented any conclusive comparisons regarding morbidity among groups. This issue is well known in surgery 122 -124 . There are some pitfalls in comparison of ALPPS with other strategies. Like every new surgical procedure, ALPPS clearly suffered from a learning curve, patient selection and indications. It appears that at least nine ALPPS procedures are required to achieve a reduction in postoperative morbidity and mortality 125 . The recent expert meeting on ALPPS produced eight recommendations providing new insights into patient selection, indications, preoperative evaluation, postoperative complications and surgical techniques 126, 127 . ALPPS is recommended in the treatment of colorectal liver metastases. Before proceeding to stage 2, an evaluation of liver function should be performed. However, the recommendations regarding ALPPS versus PVE or PVL are less clear, and ALPPS was defined only as a viable alternative to PVE or PVL. Furthermore, it is still unclear whether ALPPS has similar or better oncological outcomes than PVE or PVL. To assess oncological outcomes conclusively, the ALPPS procedure for colorectal liver metastases should be compared with PVE and/or PVL in RCTs.
Although some claims have been made about novel strategies, such as hepatic vein occlusion or bile duct ligation, only one report 17 exists in humans on the combination of PVE and hepatic vein occlusion. In that study, the gain in FLR induced by additional hepatic vein occlusion was only 4 per cent, compared with FLR hypertrophy after PVE alone.
This systematic review has inherent limitations, mostly related to the low evidence of most published information; there were only two studies with evidence level 1c 18 and 2c 30 . Many studies have examined a heterogeneous population including patients with cirrhosis or cholestasis, and the use of preoperative chemotherapy. The number of deportalized liver segments was different after PVE and PVL. In the PVE group, different embolization materials and methodology were used across the studies, which could have affected outcomes. A few patients in the ALPPS group underwent salvage ALPPS after failed PVE 34 . As the level of evidence to support the superiority of one strategy over the other is low, especially with regard to oncological outcomes, a randomized trial should be conducted for better assessment of ALPPS compared with other available strategies.
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